Complex diseases affect us all. Illumina is committed to advancing our understanding of complex diseases and how they will be diagnosed and treated.
Complex diseases result from a combination of genetic and environmental factors, many of which are not understood. These diseases include neurodegenerative diseases, psychiatric, autoimmune disorders, and others.
Illumina's expanding complex disease product portfolio includes array and next-generation sequencing (NGS) technologies that are helping drive a revolution in complex disease genomics. Complete solutions deliver high-quality, reproducible results that accelerate research in various complex diseases. These discoveries have the potential to lead to life-changing improvements for patients and their loved ones.
We are at a tipping point in genomics, where scientists and researchers continue to translate the power of the genome from science to discoveries and applications. We encourage you to take a moment to reflect what the power of the genome means for complex diseases and share it. Educate others. Promote the promise of the genome.Learn More